Myeloid Malignancies Supportive Care Protocol
Primary Stack
Core supplements with strongest evidenceDeficiency common in blood cancers; may support immune function and treatment response; promotes differentiation
Anti-inflammatory; may support treatment response and reduce inflammation
Supporting Studies (1)
Supporting Stack
Additional supplements for enhanced resultsSupports immune function; high-dose IV studied in AML (TET2 mutations); oral supports general health
Supporting Studies (1)
Supports immune function; often depleted in cancer patients; important for wound healing
Supporting Studies (1)
Supports gut health during treatment; may reduce infections; helps with treatment side effects
Supporting Studies (1)
May reduce mucositis and support gut barrier during chemotherapy
Supporting Studies (1)
For iron deficiency anemia (not iron overload); must monitor iron status carefully
Supporting Studies (1)
Anti-inflammatory; studied for potential anti-leukemic effects; may enhance chemotherapy
Supporting Studies (1)
Studied for anti-leukemic properties; may support treatment in some contexts
How This Protocol Works
Simple Explanation
Myeloid malignancies are blood cancers that arise from myeloid cells in the bone marrow. They include:
CRITICAL: These are serious cancers requiring expert hematologist/oncologist care. Treatment varies by type and may include chemotherapy, targeted therapy, hypomethylating agents, stem cell transplant, or supportive care. These supplements may support overall health during treatment but are NOT treatments for cancer. ALWAYS discuss supplements with your oncology team - some may interact with chemotherapy or other treatments.
IMPORTANT CONSIDERATIONS:
* Vitamin D deficiency is common and associated with worse outcomes. Supplementation may support treatment response.
* Omega-3 Fatty Acids have anti-inflammatory effects and may support overall health.
* Zinc supports immune function and wound healing.
* Glutamine may help reduce chemotherapy-related mouth sores (mucositis).
* Probiotics may support gut health but discuss with your team regarding neutropenic precautions.
Expected outcomes: Supplements provide supportive care during treatment. Work closely with your oncology team for appropriate timing and dosing.
Clinical Perspective
Myeloid malignancies: clonal disorders of myeloid progenitors. Classification: AML (acute, >20% blasts, medical emergency), MDS (cytopenias, dysplasia, <20% blasts, risk of AML transformation), MPN (JAK2/CALR/MPL mutations - PV, ET, PMF), CML (BCR-ABL1 positive). Risk stratification: cytogenetics, molecular (FLT3, NPM1, IDH1/2, TP53, etc.).
CRITICAL: Oncology-directed treatment. AML: induction chemotherapy (7+3 or similar), consolidation, consider allo-HSCT for intermediate/high-risk; targeted agents (midostaurin for FLT3+, venetoclax-azacitidine for unfit). MDS: low-risk - watch and wait, EPO, lenalidomide (del5q); high-risk - hypomethylating agents (azacitidine, decitabine), allo-HSCT if eligible. MPN: hydroxyurea, ruxolitinib (myelofibrosis), interferon. CML: TKIs (imatinib, dasatinib, nilotinib). Supplements are SUPPORTIVE and must be coordinated with treatment team.
* Vitamin D (B-grade): Common deficiency; prognostic in AML. Systematic review: AML (PMID: 23321246). Study: MDS (PMID: 26706006). 2000-4000 IU daily; target 40-60 ng/mL.
* Omega-3 Fatty Acids (B-grade): Anti-inflammatory. Review: hematologic malignancies (PMID: 26337781). 2-3g EPA+DHA daily.
* Vitamin C (C-grade): Interest in TET2-mutant AML (restores function). Review: epigenetics (PMID: 28072760). High-dose IV in trials only. Oral 500-1000mg daily.
* Zinc (B-grade): Immune support. Systematic review: cancer (PMID: 26040739). 15-30mg daily.
* Probiotics (C-grade): Gut support; infection prevention. Review: (PMID: 29706290). Caution in severe neutropenia. 10-20 billion CFU when counts adequate.
* Glutamine (B-grade): Mucositis reduction. Systematic review: (PMID: 27769115). 10-30g daily during chemo.
* Iron (B-grade): Complex - deficiency vs overload. Review: management (PMID: 28339170). Only supplement if iron-deficient; most transfused patients iron-overloaded (need chelation).
* Curcumin (C-grade): Anti-leukemic mechanisms studied. Review: (PMID: 23239182). 500-1000mg daily.
* Green Tea/EGCG (C-grade): CLL study (not myeloid). Trial: early CLL (PMID: 21880674). 400-800mg daily.
Assessment targets: CBC, differential, blast percentage, molecular markers, bone marrow biopsy, performance status, quality of life.
Protocol notes: Transfusion-dependent patients: iron overload is major concern - ferritin monitoring; chelation (deferasirox) when indicated. Don't supplement iron unless truly deficient. Neutropenic precautions: avoid high-risk foods; probiotics controversial in severe neutropenia - some centers allow specific strains. Antioxidants and chemotherapy: theoretical concern about reducing ROS-mediated chemo effects; no definitive answer; many oncologists suggest avoiding high-dose antioxidants during active chemo. Supplement-drug interactions: green tea may reduce bortezomib efficacy (CLL); curcumin may affect drug metabolism; discuss all supplements with oncology team. Nutrition: malnutrition common and worsens outcomes; adequate protein essential; may need tube feeding if severe mucositis. Mucositis: oral cryotherapy during certain chemos; glutamine oral rinse; good oral hygiene; magic mouthwash for pain. Infection prevention: handwashing, avoid sick contacts, may need prophylactic antibiotics/antifungals. Fatigue: extremely common; pacing, gentle exercise when counts allow, treat anemia. Quality of life: palliative care involvement beneficial even with curative intent treatment. Clinical trials: strongly consider - access to newest treatments. Second malignancies: some treatments increase risk - long-term surveillance needed.